WO2006008294A3 - Diagnostic and therapeutic use of slim3 for neurodegenerative diseases - Google Patents
Diagnostic and therapeutic use of slim3 for neurodegenerative diseases Download PDFInfo
- Publication number
- WO2006008294A3 WO2006008294A3 PCT/EP2005/053468 EP2005053468W WO2006008294A3 WO 2006008294 A3 WO2006008294 A3 WO 2006008294A3 EP 2005053468 W EP2005053468 W EP 2005053468W WO 2006008294 A3 WO2006008294 A3 WO 2006008294A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- slim3
- disease
- alzheimer
- provides
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05777722A EP1771578A2 (en) | 2004-07-23 | 2005-07-19 | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59037204P | 2004-07-23 | 2004-07-23 | |
US60/590,372 | 2004-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006008294A2 WO2006008294A2 (en) | 2006-01-26 |
WO2006008294A3 true WO2006008294A3 (en) | 2006-10-19 |
Family
ID=35785591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/053468 WO2006008294A2 (en) | 2004-07-23 | 2005-07-19 | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1771578A2 (en) |
WO (1) | WO2006008294A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016636A2 (en) * | 2000-08-24 | 2002-02-28 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders |
WO2003054152A2 (en) * | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
WO2003100092A2 (en) * | 2002-05-28 | 2003-12-04 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases |
EP1491895A1 (en) * | 2003-06-24 | 2004-12-29 | Universitätsklinikum Freiburg | Modulation of osteoblast activity by Fhl2 |
-
2005
- 2005-07-19 EP EP05777722A patent/EP1771578A2/en not_active Withdrawn
- 2005-07-19 WO PCT/EP2005/053468 patent/WO2006008294A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016636A2 (en) * | 2000-08-24 | 2002-02-28 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders |
WO2003054152A2 (en) * | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
WO2003100092A2 (en) * | 2002-05-28 | 2003-12-04 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases |
EP1491895A1 (en) * | 2003-06-24 | 2004-12-29 | Universitätsklinikum Freiburg | Modulation of osteoblast activity by Fhl2 |
Non-Patent Citations (6)
Title |
---|
"Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.", NEUROBIOLOGY OF AGING. UNITED STATES 1998 MAR-APR, vol. 19, no. 2, March 1998 (1998-03-01), pages 109 - 116, XP002233088, ISSN: 0197-4580 * |
ALBRECHT C ET AL: "Spatio - temporal gene expression profiling in Alzheimer's disease.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 202.18 URL - http://sf, XP008062372 * |
CHAN K K ET AL: "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 210, no. 2, 14 April 1998 (1998-04-14), pages 345 - 350, XP004118187, ISSN: 0378-1119 * |
DATABASE UniProt [online] 1 November 1997 (1997-11-01), "Four and a half LIM domains protein 2 (FHL-2) (Skeletal muscle LIM- protein 3) (SLIM 3) (LIM-domain protein DRAL).", XP002377336, retrieved from EBI accession no. UNIPROT:FHL2_HUMAN Database accession no. FHL2_HUMAN * |
LORING J F ET AL: "A gene expression profile of Alzheimer's disease.", DNA AND CELL BIOLOGY. UNITED STATES NOV 2001, vol. 20, no. 11, November 2001 (2001-11-01), pages 683 - 695, XP002233087, ISSN: 1044-5498 * |
TANAHASHI H ET AL: "Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein.", HUMAN MOLECULAR GENETICS. 22 SEP 2000, vol. 9, no. 15, 22 September 2000 (2000-09-22), pages 2281 - 2289, XP002374761, ISSN: 0964-6906 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006008294A2 (en) | 2006-01-26 |
EP1771578A2 (en) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
WO2006125830A3 (en) | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases | |
WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
WO2003040183A3 (en) | Compounds for the diagnosis/prevention/treatment of alzheimer's disease | |
WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
WO2006134128A3 (en) | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases | |
WO2005085472A3 (en) | Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases | |
WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
WO2003087403A3 (en) | Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases | |
WO2005101014A3 (en) | Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases | |
WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
ATE464567T1 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN ALZHEIMER'S DISEASE AND RELATED NEURODEGENERATIVE DISEASES | |
WO2006008294A3 (en) | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases | |
WO2003100092A3 (en) | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases | |
WO2004035823A3 (en) | Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases | |
ATE534751T1 (en) | USE OF PRKX FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | |
WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases | |
WO2005071418A3 (en) | Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases | |
WO2004020665A3 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases | |
WO2003069347A3 (en) | Diagnostic and therapeutic use of caps | |
WO2003104811A3 (en) | Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005777722 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005777722 Country of ref document: EP |